30th EADV virtual congress 2021

[object Object]

30th EADV virtual congress 2021

SATELLITE SYMPOSIUM INDUSTRY HUB

28 Settembre 2021 - 01 Ottobre 2021

Partecipazione riservata solo ai medici iscritti a EADV 2021.
banner evento

A guide through the maze: tackling the multifaceted challenges of living with psoriasis

Faculty
Anthony Bewley (UK) (Scientifific Committee)
Diamant Thaçi (Germany) (Scientifific Committee)

Learning objectives
After this meeting, participants should be able to:

  • Assess the mental impact of psoriasis on patients and consider psychological aspects in the decision-making process
  • Understand the importance of early diagnosis and treatment for the course of the disease, long-term remission, and quality of life
  • Integrate insights about safety, efficacy, and patient-reported outcomes into clinical practice
  • Evaluate best practices for the management of patients with psoriasis during the COVID-19 pandemic

Diving deep: harnessing the potential of the IL-23 pathway

Faculty
Jo Lambert (Belgium) (Scientifific Committee)
Bruce Strober (USA) (Scientifific Committee)

Learning objectives
After this symposium, participants should be able to:

  • Explain the tissue-specific effects and the potential for achieving long-term remission of different treatments
  • Integrate insights from randomized controlled trials and real-world evidence regarding safety, efficacy, and patient-reported outcomes into clinical practice
  • Understand the importance of early diagnosis and treatment for the disease course and for long-term remission

    Remember to forget me: the disease-modifying potential of targeting tissue-resident memory cells in psoriasis

    Faculty

    James Krueger (USA) (Scientifific Committee)
    Tiago Matos (Netherlands) (Scientifific Committee)

    Learning objectives
    After this event, participants should be able to:

    • Explain the tissue-specific effects and the potential of different treatments for achieving long-term remission
    • Define factors that allow treatment personalization, treating-to-target, and increasing treatment intervals

    The dermatologist’s guide to the clearance of the skin

    Faculty
    Kilian Eyerich (Sweden) (Scientifific Committee)
    Brian Kirby (Ireland) (Scientifific Committee)

    Learning objectives
    After this symposium, participants should be able to:

    • Define factors that allow treatment personalization, treating-to-target, and increased treatment intervals
    • Integrate insights from real-world evidence and clinical trials regarding long-term safety, efficacy, and patient-reported outcomes into clinical practice
    • Evaluate the benefits of a multidisciplinary approach to the management of psoriasis and its comorbidities

    The road to safety: a clinical dialogue on the safety of biologics in psoriasis

    Faculty
    Kenneth Gordon (USA) (Scientifific Committee)
    Elke de Jong (Netherlands) (Scientifific Committee)

    Learning objectives

    After this event, participants should be able to:

    • Analyse the current guidelines and the comparative efficacy and safety of different drug classes in the domains of psoriasis and psoriatic arthritis
    • Integrate safety data from randomized controlled trials and real-world evidence into clinical practice

    The art of joint forces: crafting psoriatic arthritis care for dermatologists

    Faculty
    Alexander Egeberg (Denmark) (Scientifific Committee)
    Laura Savage (UK) (Scientifific Committee)

    Learning objectives

    After this symposium, participants should be able to:

    • Understand the importance of early diagnosis and treatment for the disease course and for long-term remission
    • Evaluate the benefits of a multidisciplinary approach to the management of psoriasis, the different domains of psoriatic arthritis, and their comorbidities
    • Integrate insights from randomized controlled trials and real-world evidence regarding safety, efficacy, and patient-reported outcomes into clinical practice